Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts

Molecular Cancer Research

Volumn 6, Issue 5, 2008, Pages 770-784

  Li, Qunfang ^a   Tang, Lin ^a   Roberts, Paul Christopher ^a,b   Kraniak, Janice M ^a   Fridman, Aviva Levine ^a   Kulaeva, Olga I ^a   Tehrani, Omid S ^a   Tainsky, Michael A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN P53; ALPHA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, HUMAN; IRF7 PROTEIN, HUMAN;

ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; EARLY CANCER; FAMILIAL CANCER; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE SILENCING; GENETIC EPIGENESIS; GERM LINE; GROWTH INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SENESCENCE; BIOLOGICAL MODEL; CELL AGING; CELL LINE; CELL PROLIFERATION; DNA METHYLATION; FIBROBLAST; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL AGING; CELL LINE; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; INTERFERONS; LI-FRAUMENI SYNDROME; MODELS, BIOLOGICAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 51049098551     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0114     Document Type: Article

References (58)

1. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-36.
2. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
3. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63:2705-15.
4. Li FP, Fraumeni JF, Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969;43:1365-73.
5. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313-20.
6. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
7. Bischoff FZ, Strong LC, Yim SO, et al. Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome. Oncogene 1991;6:183-6.
8. Bischoff FZ, Yim SO, Pathak S, et al. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 1990;50:7979-84.
9. Neumeister P, Albanese C, Balent B, et al. Senescence and epigenetic dysregulation in cancer. Int J Biochem Cell Biol 2002;34:1475-90.
10. Fridman AL, Tang L, Kulaeva OI, et al. Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeleton. J Gerontol A Biol Sci Med Sci 2006;61:879-89.
11. Gollahon LS, Kraus E, Wu TA, et al. Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts. Oncogene 1998;17:709-17.
12. Shemer R, Birger Y, Dean WL, et al. Dynamic methylation adjustment and counting as part of imprinting mechanisms. Proc Natl Acad Sci U S A 1996;93:6371-6.
13. Robertson KD. DNA methylation and chromatin - unraveling the tangled web. Oncogene 2002;21:5361-79.
14. Kremenskoy M, Kremenska Y, Ohgane J, et al. Genome-wide analysis of DNA methylation status of CpG islands in embryoid bodies, teratomas, and fetuses. Biochem Biophys Res Commun 2003;311:884-90.
15. Deobagkar DD, Chandra HS. The inactive X chromosome in the human female is enriched in 5-methylcytosine to an unusual degree and appears to contain more of this modified nucleotide than the remainder of the genome. J Genet 2003;82:13-6.
16. Wilson VL, Jones PA. DNA methylation decreases in aging but not in immortal cells. Science 1983;220:1055-7.
17. House MG, Wistuba II, Argani P, et al. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol 2003;10:882-9.
18. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003;94:589-92.
19. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
20. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.
21. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
22. Paz MF, Fraga MF, Avila S, et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003;63:1114-21.
23. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
24. Vogt M, Haggblom C, Yeargin J, et al. Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts. Cell Growth Differ 1998;9:139-46.
25. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol Ther 1995;65:19-46.
26. Kulaeva OI, Draghici S, Tang L, et al. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003;22:4118-27.
27. Platanias LC. Interferons: laboratory to clinic investigations. Curr Opin Oncol 1995;7:560-5.
28. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
29. Mamane Y, Heylbroeck C, Genin P, et al. Interferon regulatory factors: the next generation. Gene 1999;237:1-14.
30. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997;8:293-312.
31. Doyle S, Vaidya S, O'Connell R, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002;17:251-63.
32. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-a genes by positive feedback through interferon regulatory factor-7. EMBO J 1998;17:6660-9.
33. Au WC, Moore PA, LaFleur DW, et al. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J Biol Chem 1998;273:29210-7.
34. Sato M, Hata N, Asagiri M, et al. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 1998;441:106-10.
35. Lu R, Au WC, Yeow WS, et al. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem 2000;275:31805-12.
36. Fukasawa M, Kimura M, Morita S, et al. Microarray analysis of promoter methylation in lung cancers. J Hum Genet 2006;51:368-74.
37. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon a genes. J Biol Chem 2001;276:23382-90.
38. Barnes BJ, Kellum MJ, Pinder KE, et al. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003;63:6424-31.
39. Heylbroeck C, Balachandran S, Servant MJ, et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 2000;74:3781-92.
40. Mori T, Anazawa Y, Iiizumi M, et al. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002;21:2914-8.
41. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995;376:596-9.
42. Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000;10:73-81.
43. Tang L, Roberts PC, Kraniak JM, et al. Stat1 expression is not sufficient to regulate the interferon signaling pathway in cellular immortalization. J Interferon Cytokine Res 2006;26:14-26.
44. Yaar M, Karassik RL, Schnipper LE, Gilchrest BA. Effects of α and β interferons on cultured human keratinocytes. J Invest Dermatol 1985;85:70-4.
45. Damdinsuren B, Nagano H, Wada H, et al. Stronger growth-inhibitory effect of interferon (IFN)-β compared with IFN-α is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol 2007;30:201-8.
46. Bielenberg DR, McCarty MF, Bucana CD, et al. Expression of interferon-β is associated with growth arrest of murine and human epidermal cells. J Invest Dermatol 1999;112:802-9.
47. Dong Z, Greene G, Pettaway C, et al. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res 1999;59:872-9.
48. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
49. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
50. Balachandran S, Roberts PC, Kipperman T, et al. α/β interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. J Virol 2000;74:1513-23.
51. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002;22:5721-40.
52. Cheng TF, Brzostek S, Ando O, et al. Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J Immunol 2006;176:7462-70.
53. Du M, Beatty LG, Zhou W, et al. Insulator and silencer sequences in the imprinted region of human chromosome 11p15.5. Hum Mol Genet 2003;12:1927-39.
54. Ning S, Huye LE, Pagano JS. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling. J Biol Chem 2005;280:12262-70.
55. Barnes BJ, Richards J, Mancl M, et al. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004;279:45194-207.
56. Alcorta DA, Xiong Y, Phelps D, et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 1996;93:13742-7.
57. Rogan EM, Bryan TM, Hukku B, et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995;15:4745-53.
58. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 1999;19:2109-17.